| 2026-08-12 | Deck | Corporate Presentation |
| 2026-08-12 | Press release | Kura Oncology Reports Second Quarter 2026 Financial Results |
| 2026-08-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-12 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-10 | Press release | Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Ac |
| 2026-08-07 | Press release | Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-05 | Press release | Kura Oncology to Report Second Quarter Financial Results · 2026 |
| 2026-07-29 | 8-K | Form 8-K, Item 5.02 |
| 2026-07-27 | Deck | KCRS Investor Presentation |
| 2026-07-27 | Press release | Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal |
| 2026-07-14 | Press release | Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targ |
| 2026-07-03 | Press release | Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-12 | Deck | EHA Investor Presentation |
| 2026-06-11 | Press release | Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML |
| 2026-06-05 | Press release | Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-04 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-03 | Press release | Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy |
| 2026-06-03 | Deck | ASCO Investor Presentation |
| 2026-05-12 | Press release | Kura Oncology Reports First Quarter 2026 Financial Results |
| 2026-05-12 | Deck | Corporate Presentation |
| 2026-05-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-12 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-05 | Press release | Kura Oncology to Report First Quarter 2026 Financial Results |
| 2026-04-17 | Deck | IKCS Virtual Investor Event |
| 2026-04-10 | Proxy | Definitive proxy statement |
| 2026-03-05 | Press release | Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-03-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-05 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-26 | Press release | Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results |
| 2026-01-29 | 8-K | Form 8-K, Item 5.03 |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |
| 2025-12-08 | Deck | ASH Investor Presentation |
| 2025-12-02 | 8-K | Form 8-K, Item 8.01 |
| 2025-11-13 | Deck | KOMZIFTI FDA Approval |
| 2025-11-13 | 8-K | Form 8-K, Item 8.01 |
| 2025-11-04 | Press release | Kura Oncology Reports Third Quarter 2025 Financial Results |
| 2025-11-04 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-04 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-28 | Press release | Kura Oncology to Report Third Quarter 2025 Financial Results |
| 2025-10-24 | 8-K | Form 8-K, Item 8.01 |